Denosumab-bmwo Injection
Product Images NDC 72606-058

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Denosumab-bmwo (NDC 72606-058). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celltrion Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Stoboclo 01)

An instructional diagram showing a syringe used for Denosumab-BMWO 60 mg/mL subcutaneous injection. The illustration compares the syringe before and after use, labeling parts including the plunger rod, finger flange, viewing window, safety guard, needle, and cap.*

FDA Label Image

Image (Stoboclo 02)

An instructional illustration showing a hand holding a Denosumab-BMWO injection device while a second hand is removing the cap from the needle. The image includes a recycling or disposal symbol indicating where to discard the used needle cap safely.*

FDA Label Image

Image (Stoboclo 03)

An instructional anatomical illustration showing preferred subcutaneous injection sites on the human body. Highlighted areas include the outer upper arms, the abdomen (avoiding the navel), and the anterior thighs, indicating common locations for subcutaneous injections.*

FDA Label Image

Image (Stoboclo 04)

An instructional illustration depicting the proper use of the Denosumab-BMWO 60 mg/mL subcutaneous injection. It shows a hand holding the prefilled injection device poised for administration with an inset emphasizing the injection site and needle engagement.*

FDA Label Image

Image (Stoboclo 05)

An instructional illustration showing a hand holding a syringe with a needle cover. A black arrow indicates the direction to remove the needle cover from the syringe prior to subcutaneous injection. The image emphasizes proper syringe preparation for injection.*

FDA Label Image

Chemical Structure (Stoboclo 06)

A line graph showing patient hip fracture incidence (%) over 36 study months comparing denosumab and placebo groups. The x-axis represents study months from 0 to 36, and the y-axis shows patient hip fracture incidence from 0 to 10%. Two lines are plotted: a solid line for denosumab (N=3902) and a dashed line for placebo (N=3906), indicating lower incidence in the denosumab group throughout the study.*

FDA Label Image

Principal Display Panel (60 mg/mL Syringe Carton)

Denosumab-BMWO 60 mg/mL injection carton label for a single-dose prefilled syringe with safety guard. The product is for subcutaneous use only and is manufactured by CELLTRION Inc., Republic of Korea, and distributed by CELLTRION USA, Inc. The label includes active ingredient denosumab-bmwo, additional components, usage instructions, storage information, and regulatory details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.